Treatments using your own cells to support tendon and cartilage repair
Orthocell develops autologous cell therapies designed to support the repair and regeneration of damaged tendon and cartilage tissue.
“Autologous” means the treatment uses cells collected from your own body. These cells are grown in Orthocell’s laboratory and then returned to the site of injury by a trained clinician or orthopaedic surgeon.
Orthocell’s cell therapy treatments include:
- Tendon cell therapy for chronic tendon injuries
- OrthoACITM for articular cartilage defects in the knee, patella and ankle.
These treatments may be considered when symptoms persist despite standard care, and when a specialist determines that cell therapy is suitable for your condition.
What are autologous cell therapies?
Autologous cell therapy involves collecting a small sample of the same tissue type that needs repair, isolating the required cells, growing those cells in a specialised laboratory, and then implanting them back into the area of injury. The aim is to support the body’s natural repair processes using the patient’s own cells.
Once the cells are released from the laboratory for treatment, they must be implanted within 72 hours. Transport is managed through a controlled scheduling and logistics process.
Tendon cell therapy: for chronic tendon injuries
Tenocytes are tendon cells. In tendon cell therapy, a small sample of healthy tendon is collected, and the tenocytes are grown in Orthocell’s laboratory.
Once prepared, the cells are injected into the damaged tendon, with ultrasound imaging guiding their placement.
The tendon cell therapy may be considered for patients with pain or other symptoms of tendinopathy for more than 6 months.
This tendon cell therapy is not registered on the Australian Register of Therapeutic Goods (ARTG).
This therapy may be accessed under limited circumstances through the TGA’s Special Access Scheme, where a suitably qualified clinician considers it appropriate for an individual patient.
Further, this treatment may not be suitable for everyone. A suitably qualified clinician will consider your age, medical history, allergies, current medicines, immune health, pregnancy or breastfeeding status, and the type and severity of your tendon injury before deciding whether it is appropriate for you.
OrthoACI™: cell therapy for cartilage defects
OrthoACI™ is Orthocell’s autologous chondrocyte implantation treatment for articular cartilage defects.
Chondrocytes are cartilage cells. In OrthoACI™, a small sample of healthy cartilage is collected from a non-weightbearing area of the knee. The chondrocytes are isolated, grown in the laboratory and then implanted into the cartilage defect by an orthopaedic surgeon.
OrthoACI™ may be considered for symptomatic cartilage damage in the knee, patella or ankle, including cartilage defects caused by trauma, wear or deterioration. OrthoACI is not suitable for patients with osteoarthritis, very large cartilage lesions (more than 20cm2 in total), or outside the 18–55 age range, so these eligibility limits should be clearly stated for patients seeking treatment options.
Why cartilage can be difficult to repair
Articular cartilage is the smooth tissue that covers the ends of bones inside a joint. It helps joints move smoothly and absorb load. Unlike some other tissues in the body, cartilage has a limited ability to repair itself. When cartilage damage becomes symptomatic, it can cause pain, swelling, stiffness and reduced mobility.